Recent Updates
Recently added Catalysts
KNSA Positive Sentiment

Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

Wednesday, November 12, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Kiniksa Pharmaceuticals will present at the Jefferies Global Healthcare Conference in London on November 17, 2025. The presentation will be accessible via a live webcast on the company's website, with a replay available shortly after. Kiniksa is dedicated to developing therapies for unmet medical needs, particularly in cardiovascular indications.
Price reaction · baseline $40.58 (2025-11-12 close) · hit after-hours · clean, no other KNSA news in the window
day 0 close · peak
-0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Kiniksa Pharmaceuticals is actively engaging with investors.
  • The presentation at a major conference highlights their commitment to transparency.
  • The company focuses on unmet medical needs in cardiovascular diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+62%
120-day peak, hindsight
Typical move
3.7%
average across 2 past catalysts
Lead asset
KPL-404
Phase 2 · Arthritis, Rheumatoid

Full Press Release Details

LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) --Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 2:30 p.m. Greenwich Mean Time (9:30 a.m. Eastern Time).
A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website atwww.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visitwww.kiniksa.com.

Every Second Counts!®

Kiniksa Investor & Media ContactJonathan Kirshenbaum(781) 829-3949jkirshenbaum@kiniksa.com

Frequently Asked Questions

When will Kiniksa present at the Jefferies Conference?

Kiniksa will present on November 17, 2025, at 2:30 p.m. GMT.

How can I watch Kiniksa's presentation?

The presentation will be available via a live webcast on Kiniksa's website.

What is Kiniksa's focus in biopharmaceuticals?

Kiniksa focuses on developing therapies for unmet medical needs, especially in cardiovascular diseases.

Will there be a replay of the presentation?

Yes, a replay will be available on Kiniksa's website within 48 hours after the event.

ShareAdd on Google
Tags: KNSA Kiniksa Pharmaceuticals Jefferies Global Healthcare Conference cardiovascular therapies biopharmaceutical company
Last updated: Nov 12, 2025

Biotech snapshot

Cash runway
$526M liquidity · $0M/mo burn
Low dilution risk
Lead asset
KPL-404Phase 2
Arthritis, Rheumatoid →

Catalyst track record

+62%
best trade around KNSA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for KNSA.

See every catalyst's timing & PoA →